Kanuma (Sebelipase Alfa)

Sebelipase alfa is a recombinant form of human lysosomal acid lipase. After intravenous infusion it is taken up by cells and delivered to lysosomes where it hydrolyses cholesteryl esters and triglycerides, thereby clearing stored lipids and restoring normal cellular function.

The dosing regimen for Kanuma is individualized. A qualified prescriber determines the appropriate dose, infusion rate, and frequency based on the patient’s age, weight, disease severity, and clinical response. No fixed public dosing schedule is provided.

Safety data for Kanuma in pregnancy and lactation are limited. The product is classified as pregnancy category unknown. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting therapy.

To request Kanuma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Kanuma (sebelipase alfa) is the only enzyme replacement therapy specifically approved for lysosomal acid lipase deficiency. Other approaches are mainly supportive, such as lipid‑lowering agents or dietary management. Compared with supportive care, Kanuma directly addresses the underlying enzyme deficiency, offering disease‑modifying benefits.

Kanuma should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Do not use the product if it has been exposed to temperatures outside this range.

Kanuma is supplied as a powder for solution for injection. The powder is reconstituted with the appropriate diluent and administered by intravenous infusion over a prescribed period, typically under medical supervision in a hospital or clinic setting.

Serious adverse events include anaphylaxis or severe hypersensitivity reactions, significant elevations in liver enzymes, thrombocytopenia, and renal impairment. Patients should be monitored closely during and after infusion, and any signs of severe reaction should prompt immediate medical attention.

Kanuma is contraindicated in individuals with a known hypersensitivity to sebelipase alfa or any component of the formulation. Caution is also advised for patients with severe hepatic impairment or those who have experienced severe infusion‑related reactions in the past.